What is Hemispherian?
Hemispherian is an innovative pharmaceutical company based in Oslo, Norway, dedicated to the development of a novel class of small molecule drugs known as GLIX compounds. These compounds are designed to target the TET2 enzyme, thereby activating the DNA damage response pathway to induce cancer cell death. The company's lead candidate, GLIX1, is currently in late-stage preclinical development for the treatment of glioblastoma multiforme, a particularly aggressive form of brain cancer. In addition to its therapeutic development, Hemispherian is also focused on creating a companion diagnostic tool to identify patients most likely to benefit from GLIX1 treatment, aiming for a personalized medicine approach.
How much funding has Hemispherian raised?
Hemispherian has raised a total of $14.3M across 4 funding rounds:
Multiple Rounds
$14.3M
Angel/Seed (2022): $1.4M with participation from Meneldor
Grant (2022): $2.5M led by The European Innovation Council
Private Equity (2022): $7.5M supported by The European Innovation Council
Series A (2022): $2.9M featuring Kvantia, Kistefos, and Meneldor
Key Investors in Hemispherian
Kvantia
Kvantia Oy is a company focused on generating profits for its shareholders, likely through strategic investments and operational value enhancement.
Kistefos
Kistefos AS is a private investment company managing a diversified portfolio across various industries, with a primary focus on European investments and a commitment to philanthropic endeavors.
Meneldor
Meneldor provides investment opportunities in early-stage biotech and pharmaceutical companies, focusing on rigorous evaluation of scientific, market, and financial aspects before investing.
What's next for Hemispherian?
The recent major strategic investment in Hemispherian signals a pivotal moment for the company, likely enabling it to advance GLIX1 into clinical trials and further develop its companion diagnostic. This capital infusion, part of its overall enterprise-level funding, will be crucial for navigating the complex regulatory pathways and scaling operations. The company's focus on a deadly cancer like glioblastoma multiforme, coupled with a targeted therapeutic approach and diagnostic support, positions it for significant impact in oncology. Future developments will likely involve strategic partnerships and continued research to expand the application of GLIX compounds.
See full Hemispherian company page
